| # | Title | Journal | Year | Citations |
|---|
| 1 | HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS | Drug Metabolism and Disposition | 2004 | 1,533 |
| 2 | Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene | Drug Metabolism and Disposition | 1974 | 1,000 |
| 3 | DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS | Drug Metabolism and Disposition | 2004 | 870 |
| 4 | ACETAMINOPHEN-INDUCED HEPATOTOXICITY | Drug Metabolism and Disposition | 2003 | 867 |
| 5 | Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes | Drug Metabolism and Disposition | 1999 | 867 |
| 6 | THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” | Drug Metabolism and Disposition | 2006 | 764 |
| 7 | THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE | Drug Metabolism and Disposition | 2003 | 730 |
| 8 | Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite | Drug Metabolism and Disposition | 2010 | 711 |
| 9 | COMPARISON OF PRIMARY HUMAN HEPATOCYTES AND HEPATOMA CELL LINE HEPG2 WITH REGARD TO THEIR BIOTRANSFORMATION PROPERTIES | Drug Metabolism and Disposition | 2003 | 662 |
| 10 | Biotransformation of curcumin through reduction and glucuronidation in mice | Drug Metabolism and Disposition | 1999 | 627 |
| 11 | The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans | Drug Metabolism and Disposition | 2008 | 625 |
| 12 | EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS | Drug Metabolism and Disposition | 2006 | 580 |
| 13 | COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES | Drug Metabolism and Disposition | 2004 | 568 |
| 14 | Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans | Drug Metabolism and Disposition | 2009 | 561 |
| 15 | Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines | Drug Metabolism and Disposition | 2007 | 496 |
| 16 | VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES | Drug Metabolism and Disposition | 2004 | 484 |
| 17 | OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine | Drug Metabolism and Disposition | 1999 | 468 |
| 18 | THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL | Drug Metabolism and Disposition | 2005 | 434 |
| 19 | Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation | Drug Metabolism and Disposition | 2015 | 434 |
| 20 | Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities | Drug Metabolism and Disposition | 1991 | 427 |
| 21 | Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions | Drug Metabolism and Disposition | 2007 | 425 |
| 22 | Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7 | Drug Metabolism and Disposition | 2002 | 417 |
| 23 | CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes | Drug Metabolism and Disposition | 2002 | 412 |
| 24 | Structure and Stereochemistry of the Active Metabolite of Clopidogrel | Drug Metabolism and Disposition | 2002 | 408 |
| 25 | DEGRADATION OF GINSENOSIDES IN HUMANS AFTER ORAL ADMINISTRATION | Drug Metabolism and Disposition | 2003 | 408 |
| 26 | In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System | Drug Metabolism and Disposition | 2008 | 397 |
| 27 | Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes | Drug Metabolism and Disposition | 1995 | 395 |
| 28 | Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction | Drug Metabolism and Disposition | 2009 | 387 |
| 29 | Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification | Drug Metabolism and Disposition | 2015 | 381 |
| 30 | Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities | Drug Metabolism and Disposition | 2012 | 373 |
| 31 | The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin | Drug Metabolism and Disposition | 2003 | 354 |
| 32 | Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole | Drug Metabolism and Disposition | 2003 | 350 |
| 33 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds | Drug Metabolism and Disposition | 2008 | 345 |
| 34 | Metabolite Profiling of Hydroxycinnamate Derivatives in Plasma and Urine after the Ingestion of Coffee by Humans: Identification of Biomarkers of Coffee Consumption | Drug Metabolism and Disposition | 2009 | 343 |
| 35 | The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and Its Prediction from Physicochemical Properties | Drug Metabolism and Disposition | 2002 | 342 |
| 36 | A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES | Drug Metabolism and Disposition | 2005 | 334 |
| 37 | Absorption and Disposition of Ginsenosides after Oral Administration of Panax notoginseng Extract to Rats | Drug Metabolism and Disposition | 2009 | 334 |
| 38 | Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans | Drug Metabolism and Disposition | 2009 | 333 |
| 39 | Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy? | Drug Metabolism and Disposition | 2014 | 330 |
| 40 | Absorption, distribution, elimination of tea polyphenols in rats | Drug Metabolism and Disposition | 1997 | 329 |
| 41 | Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin | Drug Metabolism and Disposition | 2008 | 322 |
| 42 | Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie” | Drug Metabolism and Disposition | 2009 | 321 |
| 43 | Methylated Flavonoids Have Greatly Improved Intestinal Absorption and Metabolic Stability | Drug Metabolism and Disposition | 2006 | 319 |
| 44 | Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes | Drug Metabolism and Disposition | 2007 | 319 |
| 45 | Diversity of Mechanism-Based Pharmacodynamic Models | Drug Metabolism and Disposition | 2003 | 318 |
| 46 | Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization | Drug Metabolism and Disposition | 2002 | 317 |
| 47 | Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes | Drug Metabolism and Disposition | 2003 | 313 |
| 48 | HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID | Drug Metabolism and Disposition | 2004 | 311 |
| 49 | PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies | Drug Metabolism and Disposition | 2007 | 310 |
| 50 | Human UGT2B7 catalyzes morphine glucuronidation | Drug Metabolism and Disposition | 1997 | 309 |
